Rapport Therapeutics Inc [RAPP] stock prices are up 1.16% to $26.96 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The RAPP shares have gain 2.51% over the last week, with a monthly amount glided 84.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rapport Therapeutics Inc [NASDAQ: RAPP] stock has seen the most recent analyst activity on September 16, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $44. Previously, H.C. Wainwright started tracking the stock with Buy rating on August 06, 2025, and set its price target to $31. On April 08, 2025, Citizens JMP initiated with a Mkt Outperform rating. TD Cowen started tracking the stock assigning a Buy rating. Stifel initiated its recommendation with a Buy and recommended $35 as its price target on July 02, 2024. Jefferies started tracking with a Buy rating for this stock on July 02, 2024, and assigned it a price target of $35.
The stock price of Rapport Therapeutics Inc [RAPP] has been fluctuating between $6.43 and $42.27 over the past year. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. Rapport Therapeutics Inc [NASDAQ: RAPP] shares were valued at $26.96 at the most recent close of the market. An investor can expect a potential return of 63.2% based on the average RAPP price forecast.
Analyzing the RAPP fundamentals
Gross Profit Margin for this corporation currently stands at -0.49% with Operating Profit Margin at -141.34%, Pretax Profit Margin comes in at -122.66%, and Net Profit Margin reading is -122.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.3 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.93 points at the first support level, and at 24.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.82, and for the 2nd resistance point, it is at 28.69.
Ratios To Look Out For
It’s worth pointing out that Rapport Therapeutics Inc [NASDAQ:RAPP]’s Current Ratio is 22.75. On the other hand, the Quick Ratio is 22.75, and the Cash Ratio is 4.64.
Transactions by insiders
Recent insider trading involved Ceesay Abraham, Chief Executive Officer, that happened on Sep 17 ’25 when 40835.0 shares were sold. Chief Executive Officer, Ceesay Abraham completed a deal on Sep 17 ’25 to sell 35585.0 shares. Meanwhile, Director ABRAHAM CEESAY bought 52501.0 shares on Sep 17 ’25.
